XomaXOMA
XOMA
About: XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Employees: 13
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
1% more capital invested
Capital invested by funds: $203M [Q3] → $205M (+$1.64M) [Q4]
0.58% more ownership
Funds ownership: 65.75% [Q3] → 66.33% (+0.58%) [Q4]
3% less funds holding
Funds holding: 67 [Q3] → 65 (-2) [Q4]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
53% less call options, than puts
Call options by funds: $32K | Put options by funds: $68K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
43%
upside
Avg. target
$70
183%
upside
High target
$104
324%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Benchmark Robert Wasserman 29% 1-year accuracy 12 / 42 met price target | 43%upside $35 | Buy Initiated | 17 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 19% 1-year accuracy 79 / 412 met price target | 324%upside $104 | Buy Reiterated | 28 Mar 2025 |
Financial journalist opinion
Based on 4 articles about XOMA published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens
Neutral
Accesswire
2 weeks ago
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP).
Positive
Seeking Alpha
2 weeks ago
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
XOMA aggregates future biotech royalties and milestone rights for stable, diversified revenue streams. However, I believe its preferred shares (under tickers XOMAO and XOMAP) offer attractive yields with cumulative, perpetual dividends. Since XOMA's diversified portfolio features high-potential, recently FDA-approved assets like Ojemda and Miplyffa, I also think the yields should be relatively secure.
Neutral
GlobeNewsWire
3 weeks ago
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025.
Neutral
GlobeNewsWire
1 month ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:
Neutral
GlobeNewsWire
1 month ago
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024
Neutral
GlobeNewsWire
2 months ago
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullosa (DEB).
Neutral
GlobeNewsWire
2 months ago
XOMA Royalty to Present at Investor Conferences in March
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March. Management will also participate in one-on-one investor meetings.
Neutral
GlobeNewsWire
2 months ago
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025.
Neutral
GlobeNewsWire
4 months ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.
Charts implemented using Lightweight Charts™